Evotec SE
NASDAQ:EVODrug Manufacturers - Specialty & Generic
-$0.02 today
- Market cap
- $518.56M
- Beta
- 1.30
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$1.09
Volume 0.04M
Average 0.08M
EVO Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Evotec SENASDAQ: EVO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of €123.94M (cash outflow) rose 292.5% year over year, ahead of the -8.5% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at -17.3% a year.
Context
- Net income amounted to 13.1% of revenue in FY2025, down 11.5 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -€254.23M (+155.7%) for the fiscal year ending Dec 2026, a step up from the -49.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -€123.94M-955.5% QoQ
- Last fiscal yearDec 2025
- -€99.43M-49.3% YoY
- LTMMar 2026
- -€196.02M-8.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +292.5% | -71.4% | -363.9 pp |
| 1 year | -49.3% | +155.7% | +205.0 pp |
| 3-year CAGR | -17.3% | -76.3% | -59.0 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
EUR · from the cash flow
- Latest · FY2025
- (99.43M) EUR
- Year-over-year change
- +49.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (99.43M) | +49.3% |
| FY2024 | 2024-12-31 | (196.08M) | -133.7% |
| FY2023 | 2023-12-31 | (83.91M) | +52.2% |
| FY2022 | 2022-12-31 | (175.66M) | -181.5% |
| FY2021 | 2021-12-31 | 215.51M | — |
Net Income vs competitors
How EVO compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -8.5% is the 8th highest of 11, against a peer median of +23.0%.
- Net income amounts to 26.3% of revenue for EVO, versus a peer median of 16.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Feb 2026 | $1.83B USD | +35.0% | +70.9% | 154.9% | |
| LTM Sep 2026 | $263.86M USD | +77.1% | +22.8% | 291.6% | |
| LTM Mar 2026 | €196.02M EUR | -8.5% | -17.3% | 26.3% | |
| LTM Sep 2026 | €179.96M EUR | +11.0% | +31.9% | — | |
| LTM Mar 2026 | $173.05M USD | +5.4% | +13.8% | 25.7% | |
| LTM Mar 2026 | $171.15M USD | -83.1% | -75.5% | 6.8% | |
| LTM Sep 2026 | $166.99M USD | +199.5% | +125.1% | 26.9% | |
| LTM Mar 2026 | $80.73M USD | -183.6% | — | 14.4% | |
| LTM Sep 2026 | $44.01M USD | +125.0% | -11.5% | 16.3% | |
| LTM Mar 2026 | $14.96M USD | -31.0% | -28.5% | 5.6% | |
| LTM Mar 2026 | $5.14M USD | +105.0% | -23.8% | 0.7% | |
| Peer median (excluding EVO) | — | +23.0% | +13.8% | 16.3% | |
Competitors are the stored peer set for EVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 215.51M | (175.66M) | (83.91M) | (196.08M) | (99.43M) |
| Depreciation & Amortization | 67.61M | 83.2M | 92.98M | 101.62M | 95.55M |
| Deferred Income Tax | 5.07M | 21.7M | 3.32M | 2.1M | 14.11M |
| Stock-Based Compensation | 7.81M | 9.92M | 9.63M | 5.04M | 0 |
| Change in Working Capital | (2.28M) | 105.29M | (9.94M) | (68.21M) | (58.4M) |
| Accounts Receivables | (48.03M) | (53.68M) | 0 | 0 | (27.6M) |
| Inventory | (11.65M) | (4.41M) | 0 | 0 | (9.18M) |
| Accounts Payables | 31.34M | 24.55M | 0 | 0 | (7.02M) |
| Other Working Capital | 26.06M | 138.83M | (9.94M) | (68.21M) | (14.61M) |
| Other Non-Cash Items | (171.47M) | 161.37M | 24.37M | 173.75M | 39.11M |
| Operating Cash Flow | 122.24M | 205.81M | 36.44M | 18.22M | (9.06M) |
| Capital Expenditures | (118.94M) | (181.35M) | (216M) | (132.24M) | (69.68M) |
| Acquisitions (Net) | (21.09M) | (83.82M) | (20.16M) | 42.78M | 213.76M |
| Purchases of Investments | (123.7M) | (355.82M) | (48.39M) | (29.39M) | (13.42M) |
| Sales of Investments | 27.25M | 205.17M | 260.36M | 35.67M | 38.87M |
| Other Investing Activities | (7.38M) | 3.03M | 8.22M | (2.78M) | 0 |
| Investing Cash Flow | (243.86M) | (412.8M) | (13.29M) | (71.19M) | 159.86M |
| Debt Repayment | 14.77M | (53.11M) | 84.6M | (152.07M) | (6.96M) |
| Common Stock Issued | 404.32M | 355K | 0 | 0 | (1.27M) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (20.67M) | (5.39M) | (12.63M) | (9.35M) | (22.71M) |
| Financing Cash Flow | 398.43M | (58.15M) | 71.96M | (161.42M) | (30.93M) |
| Effect of Forex Changes | (66K) | (19.04M) | 644K | 9.87M | 28.46M |
| Net Change in Cash | 276.75M | (284.17M) | 95.75M | (204.52M) | 148.32M |
| Free Cash Flow | 3.29M | 24.46M | (179.56M) | (114.02M) | (78.74M) |
Evotec SE
NASDAQ:EVO
Intrinsic Alpha fair value
Locked
Current Price
$1.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.